It was announced today that Cork based clinical trials organization, Atlantia, has been appointed by a market leading Irish biotech company to commence a new study which will assess the impact of its food-derived ingredients on the prediabetic population.

The Irish company are industry frontrunners in the pursuit of novel and natural active food ingredients with scientifically proven health benefits while Atlantia is a global leader in commercial clinical food trials. They are looking for 56 trial participants to take part in a 12-week study programme which will be taking place over June and July.

Atlantia report that every year 34 million people globally are transitioning from borderline or prediabetes on into full blown diabetes. The aim of this study is to help prevent such a catastrophic surge into chronic illness. 

Commenting on the trial, Atlantia’s CEO, Andrea Doolan said, "We are delighted to be working on an exclusively Irish based trial that has the potential to make such a difference to a huge worldwide medical problem. We (Atlantia) have been conducting clinical trials for more than half of the top 10 food companies around the world, to measure the intake and impact of a wide range of foods and their extracts and now we are partnering with an innovative and revolutionary company who, through the use of artificial intelligence, have been revolutionizing the discovery of novel, natural and scientifically proven active ingredients that can manage and improve human health."

Source: www.businessworld.ie